Bortolami Martina, Pandolfi Fabiana, Tudino Valeria, Messore Antonella, Madia Valentina Noemi, De Vita Daniela, Di Santo Roberto, Costi Roberta, Romeo Isabella, Alcaro Stefano, Colone Marisa, Stringaro Annarita, Espargaró Alba, Sabatè Raimon, Scipione Luigi
Department of Scienze di Base e Applicate per l'Ingegneria, Sapienza University of Rome, Via Castro Laurenziano 7, 00185 Rome, Italy.
Department of Chimica e Tecnologia del Farmaco, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Pharmaceuticals (Basel). 2022 May 27;15(6):673. doi: 10.3390/ph15060673.
Alzheimer disease is an age-linked neurodegenerative disorder representing one of the greatest medical care challenges of our century. Several drugs are useful in ameliorating the symptoms, even if none could stop or reverse disease progression. The standard approach is represented by the cholinesterase inhibitors (ChEIs) that restore the levels of acetylcholine (ACh) by inhibiting the acetylcholinesterase (AChE). Still, their limited efficacy has prompted researchers to develop new ChEIs that could also reduce the oxidative stress by exhibiting antioxidant properties and by chelating the main metals involved in the disease. Recently, we developed some derivatives constituted by a 2-amino-pyrimidine or a 2-amino-pyridine moiety connected to various aromatic groups by a flexible amino-alkyl linker as new dual inhibitors of AChE and butyrylcholinesterase (BChE). Following our previous studies, in this work we explored the role of the flexible linker by replacing the amino group with an amide or a carbamic group. The most potent compounds showed higher selectivity against BChE in respect to AChE, proving also to possess a weak anti-aggregating activity toward Aβ and tau and to be able to chelate Cu and Fe ions. Molecular docking and molecular dynamic studies proposed possible binding modes with the enzymes. It is noteworthy that these compounds were predicted as BBB-permeable and showed low cytotoxicity on the human brain cell line.
阿尔茨海默病是一种与年龄相关的神经退行性疾病,是本世纪最大的医疗挑战之一。有几种药物可用于改善症状,尽管没有一种药物能够阻止或逆转疾病进展。标准方法是使用胆碱酯酶抑制剂(ChEIs),通过抑制乙酰胆碱酯酶(AChE)来恢复乙酰胆碱(ACh)水平。然而,它们有限的疗效促使研究人员开发新的ChEIs,这些新的ChEIs还可以通过展现抗氧化特性和螯合疾病中涉及的主要金属来减轻氧化应激。最近,我们开发了一些衍生物,它们由2-氨基嘧啶或2-氨基吡啶部分通过柔性氨基烷基连接体与各种芳香基团相连,作为AChE和丁酰胆碱酯酶(BChE)的新型双重抑制剂。根据我们之前的研究,在这项工作中,我们通过用酰胺或氨基甲酰基取代氨基来探索柔性连接体的作用。最有效的化合物对BChE相对于AChE表现出更高的选择性,还证明对Aβ和tau具有弱的抗聚集活性,并且能够螯合铜和铁离子。分子对接和分子动力学研究提出了与这些酶可能的结合模式。值得注意的是,这些化合物被预测为可透过血脑屏障,并且对人脑细胞系显示出低细胞毒性。